Key PointsResMed reported that core constant currency revenue grew 7% in the first quarter.

ResMed: 3 Key Takeaways for Long-Term Investors

@media (max-width: 768px) {
                .image-container {
                    width: 100% !important;
                    float: none !important;
                    margin: 0 0 1rem 0 !important;
                }
            }
        



Image source: The Mo

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed Inc. announced its financial results for the first quarter of fiscal year 2027 ended September 30, 2026. The company reported that Q1 revenue increased by 6% to $1.4 billion, driven by continued global demand for sleep and breathing health solutions. GAAP diluted earnings

ResMed Inc. Reports Q1 Fiscal Year 2027 Revenue of $1.4 billion and Declares Quarterly Cash Dividend of $0.66 per share

In trading on Wednesday, shares of ResMed Inc. (Symbol: RMD) crossed above their 200 day moving average of $225.46, changing hands as high as $228.75 per share.  ResMed Inc. shares are currently trading up about 2.7% on the day.  The chart below shows the one year performance of

ResMed Breaks Above 200-Day Moving Average - Bullish for RMD

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: https://investor.resmed.comDate

Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026

Insider reported a trade at RESMED INC

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

ResMed Inc. News